<p>SummerHaven Investment Management LLC 在第三季度購買了 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）披露的信息。該基金購買了 38,200 股公司股票，價值約為 1,018,000 美元。根據其最近向證券交易委員會（SEC）提交的文件，SummerHaven Investment Management LLC 擁有約 0.08% 的 Amphastar Pharmaceuticals。</p>
<ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
<p>其他大型投資者最近也買賣了該公司的股票。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Amphastar Pharmaceuticals 的股份增加了 5.2%。賓夕法尼亞州公共學校僱員退休系統現在擁有 9,440 股公司股票，價值 217,000 美元，此前在上個季度購買了 465 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Amphastar Pharmaceuticals 的股份增加了 2.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 現在擁有 22,489 股公司股票，價值 652,000 美元，此前在上個季度購買了 613 股。Global Retirement Partners LLC 在第三季度將其在 Amphastar Pharmaceuticals 的持股增加了 219.0%。Global Retirement Partners LLC 現在擁有 1,024 股公司股票，價值 27,000 美元，此前在上個季度購買了 703 股。Farther Finance Advisors LLC 在第三季度將其在 Amphastar Pharmaceuticals 的持股增加了 356.0%。Farther Finance Advisors LLC 現在擁有 944 股公司股票，價值 25,000 美元，此前在上個季度購買了 737 股。最後，GAMMA Investing LLC 在第二季度將其在 Amphastar Pharmaceuticals 的持股增加了 62.2%。GAMMA Investing LLC 現在擁有 2,162 股公司股票，價值 50,000 美元，此前在上個季度購買了 829 股。65.09% 的股票由機構投資者和對沖基金持有。</p>
<h2>Amphastar Pharmaceuticals 股票下跌 1.3%</h2>
<p>Amphastar Pharmaceuticals 股票在週三開盤價為 26.25 美元。Amphastar Pharmaceuticals, Inc. 的 12 個月低點為 20.39 美元，12 個月高點為 37.38 美元。該公司的市值為 12.1 億美元，市盈率為 11.62，市盈增長比率為 4.71，貝塔值為 0.89。公司的 50 日移動平均價格為 26.69 美元，200 日移動平均價格為 26.16 美元。公司的速動比率為 2.21，流動比率為 3.12，債務與股本比率為 0.78。</p>
<ul>
<li>前景看好的小型生物科技公司 Amphastar 迎來可操作的回調</li>
</ul>
<p>Amphastar Pharmaceuticals（NASDAQ:AMPH - 獲取免費報告）最後一次公佈財報是在 11 月 6 日，星期四。該公司報告每股收益為 0.93 美元，超出分析師一致預期的 0.83 美元，超出幅度為 0.10 美元。該公司在本季度的收入為 1.9184 億美元，而分析師預期為 1.8690 億美元。Amphastar Pharmaceuticals 的股本回報率為 19.70%，淨利潤率為 15.43%。作為一個整體，分析師預計 Amphastar Pharmaceuticals, Inc. 本年度將發佈 3.49 的每股收益。</p>
<h2>內部人士買賣</h2>
<p>在其他 Amphastar Pharmaceuticals 的新聞中，董事 Floyd F. Petersen 在 11 月 13 日星期四出售了 16,679 股該股票。股份以平均價格 26.49 美元出售，總交易額為 441,826.71 美元。交易後，該董事在公司中持有 75,531 股，價值 2,000,816.19 美元。這代表其持股減少了 18.09%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，董事 Richard K. Prins 在 11 月 25 日星期二出售了 4,179 股 Amphastar Pharmaceuticals 股票。股份以平均價格 27.10 美元出售，總交易額為 113,250.90 美元。交易完成後，該董事持有 35,183 股公司股票，價值約為 953,459.30 美元。該交易使其持股減少了 10.62%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士已出售 35,308 股公司股票，價值 931,637 美元。27.10% 的股票由公司內部人士持有。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師最近對 AMPH 股票發表了評論。巴克萊在 12 月 9 日星期二的研究報告中開始覆蓋 Amphastar Pharmaceuticals 的股票。他們給予該公司 “持平” 的評級，目標價格為 30.00 美元。Zacks Research 在 11 月 14 日星期五的報告中將 Amphastar Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。Needham &amp; Company LLC 在 11 月 7 日星期五的研究報告中將 Amphastar Pharmaceuticals 的目標價格從 36.00 美元下調至 34.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 12 月 29 日星期一的研究報告中重申了對 Amphastar Pharmaceuticals 股票的 “持有（c-）” 評級。兩位股票研究分析師對該股票給予了買入評級，六位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Amphastar Pharmaceuticals 的共識評級為 “持有”，平均目標價格為 31.00 美元。</p>
<p><strong>獲取我們對 Amphastar Pharmaceuticals 的最新分析</strong></p>
<h2>Amphastar Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Amphastar Pharmaceuticals, Inc. 是一家總部位於加利福尼亞州蘭喬庫卡蒙加的專業製藥公司。成立於 2004 年，Amphastar 專注於可注射和吸入產品的開發、生產和商業化。該公司在加利福尼亞的生產設施生產針對緊急和慢性醫療條件的仿製藥和專利配方。</p>
<p>Amphastar 的產品組合包括一系列可注射的仿製藥，如腎上腺素、納洛酮和利多卡因，服務於醫院、急救醫療和零售藥房渠道。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票超過 Amphastar Pharmaceuticals</li>
<li>美國的下一個權力舉動從地下開始</li>
<li>你的簽名缺失——在為時已晚之前採取行動</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>Nvidia 的三個秘密合作伙伴</li>
</ul>
<p><strong>想看看其他對 AMPH 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Amphastar Pharmaceuticals 嗎？</h2>
<p>在考慮 Amphastar Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amphastar Pharmaceuticals 並不在名單上。</p>
<p>雖然 Amphastar Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

美國制藥 ETF - iShares

Amphastar制藥

<p>SummerHaven Investment Management LLC 在第三季度收購了價值 102 萬美元的 Amphastar Pharmaceuticals 股份，購買了 38,200 股。其他機構投資者也增加了他們的持股。Amphastar 的股票目前下跌 1.3%，交易價格為 26.25 美元，市值為 12.1 億美元。該公司報告每股收益為 0.93 美元，超出預期。近期發生了內部人士的股票出售，董事們減少了他們的持股。分析師對該股票的評級不一，巴克萊給予其 “持平” 評級，並設定 30 美元的目標價</p>

<p>SummerHaven Investment Management LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,200 shares of the company's stock, valued at approximately $1,018,000. SummerHaven Investment Management LLC owned about 0.08% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>SummerHaven Investment Management LLC 在第三季度購買了 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）披露的信息。該基金購買了 38,200 股公司股票，價值約為 1,018,000 美元。根據其最近向證券交易委員會（SEC）提交的文件，SummerHaven Investment Management LLC 擁有約 0.08% 的 Amphastar Pharmaceuticals。</p>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得購買的前兩隻小型醫療股</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Amphastar Pharmaceuticals by 5.2% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company's stock worth $217,000 after purchasing an additional 465 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock valued at $652,000 after buying an additional 613 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Amphastar Pharmaceuticals by 219.0% during the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock worth $27,000 after buying an additional 703 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock worth $25,000 after buying an additional 737 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 62.2% during the second quarter. GAMMA Investing LLC now owns 2,162 shares of the company's stock worth $50,000 after acquiring an additional 829 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者最近也買賣了該公司的股票。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Amphastar Pharmaceuticals 的股份增加了 5.2%。賓夕法尼亞州公共學校僱員退休系統現在擁有 9,440 股公司股票，價值 217,000 美元，此前在上個季度購買了 465 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Amphastar Pharmaceuticals 的股份增加了 2.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 現在擁有 22,489 股公司股票，價值 652,000 美元，此前在上個季度購買了 613 股。Global Retirement Partners LLC 在第三季度將其在 Amphastar Pharmaceuticals 的持股增加了 219.0%。Global Retirement Partners LLC 現在擁有 1,024 股公司股票，價值 27,000 美元，此前在上個季度購買了 703 股。Farther Finance Advisors LLC 在第三季度將其在 Amphastar Pharmaceuticals 的持股增加了 356.0%。Farther Finance Advisors LLC 現在擁有 944 股公司股票，價值 25,000 美元，此前在上個季度購買了 737 股。最後，GAMMA Investing LLC 在第二季度將其在 Amphastar Pharmaceuticals 的持股增加了 62.2%。GAMMA Investing LLC 現在擁有 2,162 股公司股票，價值 50,000 美元，此前在上個季度購買了 829 股。65.09% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Amphastar Pharmaceuticals Stock Down 1.3%</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 股票下跌 1.3%</h2>
</div><p>Amphastar Pharmaceuticals stock opened at $26.25 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $37.38. The stock has a market cap of $1.21 billion, a P/E ratio of 11.62, a P/E/G ratio of 4.71 and a beta of 0.89. The company's 50-day moving average price is $26.69 and its two-hundred day moving average price is $26.16. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals 股票在週三開盤價為 26.25 美元。Amphastar Pharmaceuticals, Inc. 的 12 個月低點為 20.39 美元，12 個月高點為 37.38 美元。該公司的市值為 12.1 億美元，市盈率為 11.62，市盈增長比率為 4.71，貝塔值為 0.89。公司的 50 日移動平均價格為 26.69 美元，200 日移動平均價格為 26.16 美元。公司的速動比率為 2.21，流動比率為 3.12，債務與股本比率為 0.78。</p>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>前景看好的小型生物科技公司 Amphastar 迎來可操作的回調</li>
</ul>
</div><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.10. The company had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals（NASDAQ:AMPH - 獲取免費報告）最後一次公佈財報是在 11 月 6 日，星期四。該公司報告每股收益為 0.93 美元，超出分析師一致預期的 0.83 美元，超出幅度為 0.10 美元。該公司在本季度的收入為 1.9184 億美元，而分析師預期為 1.8690 億美元。Amphastar Pharmaceuticals 的股本回報率為 19.70%，淨利潤率為 15.43%。作為一個整體，分析師預計 Amphastar Pharmaceuticals, Inc. 本年度將發佈 3.49 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 16,679 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $26.49, for a total transaction of $441,826.71. Following the transaction, the director owned 75,531 shares in the company, valued at $2,000,816.19. This represents a 18.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director owned 35,183 shares of the company's stock, valued at approximately $953,459.30. The trade was a 10.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 35,308 shares of company stock valued at $931,637. 27.10% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Amphastar Pharmaceuticals 的新聞中，董事 Floyd F. Petersen 在 11 月 13 日星期四出售了 16,679 股該股票。股份以平均價格 26.49 美元出售，總交易額為 441,826.71 美元。交易後，該董事在公司中持有 75,531 股，價值 2,000,816.19 美元。這代表其持股減少了 18.09%。該出售在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，董事 Richard K. Prins 在 11 月 25 日星期二出售了 4,179 股 Amphastar Pharmaceuticals 股票。股份以平均價格 27.10 美元出售，總交易額為 113,250.90 美元。交易完成後，該董事持有 35,183 股公司股票，價值約為 953,459.30 美元。該交易使其持股減少了 10.62%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士已出售 35,308 股公司股票，價值 931,637 美元。27.10% 的股票由公司內部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research analysts have recently commented on AMPH shares. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 price objective for the company. Zacks Research cut Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Needham &amp; Company LLC dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對 AMPH 股票發表了評論。巴克萊在 12 月 9 日星期二的研究報告中開始覆蓋 Amphastar Pharmaceuticals 的股票。他們給予該公司 “持平” 的評級，目標價格為 30.00 美元。Zacks Research 在 11 月 14 日星期五的報告中將 Amphastar Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。Needham &amp; Company LLC 在 11 月 7 日星期五的研究報告中將 Amphastar Pharmaceuticals 的目標價格從 36.00 美元下調至 34.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 12 月 29 日星期一的研究報告中重申了對 Amphastar Pharmaceuticals 股票的 “持有（c-）” 評級。兩位股票研究分析師對該股票給予了買入評級，六位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，Amphastar Pharmaceuticals 的共識評級為 “持有”，平均目標價格為 31.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Amphastar Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Amphastar Pharmaceuticals 的最新分析</strong></p>
</div><h2>Amphastar Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals, Inc. 是一家總部位於加利福尼亞州蘭喬庫卡蒙加的專業製藥公司。成立於 2004 年，Amphastar 專注於可注射和吸入產品的開發、生產和商業化。該公司在加利福尼亞的生產設施生產針對緊急和慢性醫療條件的仿製藥和專利配方。</p>
</div><p>Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.</p>
<div class="lb-trans"><p>Amphastar 的產品組合包括一系列可注射的仿製藥，如腎上腺素、納洛酮和利多卡因，服務於醫院、急救醫療和零售藥房渠道。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>Nvidia’s 3 Secret Partners</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Amphastar Pharmaceuticals</li>
<li>美國的下一個權力舉動從地下開始</li>
<li>你的簽名缺失——在為時已晚之前採取行動</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>1933 年的退款：特朗普的重置可能創造即時財富</li>
<li>Nvidia 的三個秘密合作伙伴</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 AMPH 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Amphastar Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Amphastar Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Amphastar Pharmaceuticals 並不在名單上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amphastar Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

SummerHaven Investment Management LLC 在 Amphastar 製藥公司持有價值 102 萬美元的頭寸